Home

About Dr. Dahr

Location

Forms

Insurance & fees

Laser surgery

Injections

Vitreoretinal surgery

Amsler grid

Contact us

 

 

 

 

 

 

Resources

Diabetes

Macular Degeneration

Retinal Detachment

Retinal tears

Flashes & floaters

Vitreous Separation

Pucker/ERM/VMT

Macular Hole

Vein occlusions

Other retinal diseases

Unexplained vision loss

Uveitis

Melanoma

Dry Eye

Clinical Trials

Low vision

Driving

Presentations & lectures by Dr. Dahr

More education and support resources

 

Disclosure

A recent article in the New York Times as well as a recent article in the Wall Street Journal have discussed relationships doctors may have with industry and how those relationships may affect the doctor-patient relationship and doctor-patient decision making. Industry includes pharmaceutical companies, vitamin companies, device companies, imaging centers, surgery centers, etc. This issue is also being increasingly discussed within the leadership circles of the American Academy of Ophthalmology, according to a recent article in Ophthalmology Times. The overarching issue of the commercialization of medicine is succinctly discussed in a recent article in the Journal of the American Medical Association.

I wanted to make clear: I, Sam Dahr, M.D., have no financial relationship with any medical-related companies whatsoever. For example, I do not have any relationship with the manufacturers of the vitamins we recommend for patients with macular degeneration. Those recommendations are based on the AREDS clinical trial alone.

My patient recommendations are based solely on my belief as to what is best for an individual patient, based on my clinical training, analysis of available data, and clinical experience.

I have a single activity outside my practice. I serve as a consultant to the U.S. Food and Drug Administration (FDA). The reimbursement from the federal government for this activity is fairly small. Rather, I consider this activity an educational experience for myself that benefits my patients. I also consider my relationship with the FDA a form of public service.